Cannabis use as described by people with multiple sclerosis

被引:52
作者
Page, SA
Verhoef, MJ
Stebbins, RA
Metz, LM
Levy, JC
机构
[1] Univ Calgary, Off Med Bioeth, HMRB, Calgary, AB T2N 4N1, Canada
[2] Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 4N1, Canada
[3] Univ Calgary, Dept Sociol, Calgary, AB T2N 4N1, Canada
[4] Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada
[5] Univ Calgary, Fac Law, Calgary, AB T2N 4N1, Canada
关键词
D O I
10.1017/S0317167100002584
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Multiple sclerosis (MS) is one of the most common neurological diseases affecting young adults. The prevalence of MS in Alberta has been described as among the highest reported in the world, estimated at 217 per 100,000. Numerous anecdotal reports, and a few small empirical investigations have suggested that cannabis use may relieve the symptom experience of those with MS. The present study was undertaken to describe cannabis use by this patient group. Information on peoples' beliefs, practices and experiences related to use were investigated. Methods: A questionnaire was mailed to a sample of 780 adults with MS in southern Alberta, Canada. Results: Completed questionnaires were returned by 420/673 eligible subjects (response rate 62%). Mean sample age was 48 years and 75% were women. Respondents ranged from mildly to severely impaired. The majority of respondents (96%) was aware cannabis was potentially therapeutically useful for MS and most (72%) supported legalization for medicinal purposes. Forty-three percent had tried cannabis at some point in their lives, 16% for medicinal purposes. Symptoms reported to be ameliorated included anxiety/depression, spasticity and chronic pain. Reasons given for not trying cannabis were the fact that it is an illegal substance, concern about side effects and lack of knowledge on how to obtain it. Conclusions: Subjective improvements in symptom experience were reported by the majority of people with MS who currently use cannabis. Further evaluation of this substance is warranted.
引用
收藏
页码:201 / 205
页数:5
相关论文
共 32 条
[11]  
Feldman HW, 1998, J PSYCHOACTIVE DRUGS, V30, P179
[12]  
Gray C, 1998, CAN MED ASSOC J, V158, P373
[13]   SHORT-TERM EFFECTS OF SMOKING MARIJUANA ON BALANCE IN PATIENTS WITH MULTIPLE-SCLEROSIS AND NORMAL VOLUNTEERS [J].
GREENBERG, HS ;
WERNESS, SAS ;
PUGH, JE ;
ANDRUS, RO ;
ANDERSON, DJ ;
DOMINO, EF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (03) :324-328
[14]  
GRUBER AJ, 2000, PHARM NEWS, V7, P30
[15]   Adverse effects of cannabis [J].
Hall, W ;
Solowij, N .
LANCET, 1998, 352 (9140) :1611-1616
[16]   Safety, tolerability, and efficacy of orally administered cannabinoids in MS [J].
Killestein, J ;
Hoogervorst, ELJ ;
Reif, M ;
Kalkers, NF ;
van Loenen, AC ;
Staats, PGM ;
Gorter, RW ;
Uitdehaag, BMJ ;
Polman, CH .
NEUROLOGY, 2002, 58 (09) :1404-1407
[17]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[18]   NABILONE IN THE TREATMENT OF MULTIPLE-SCLEROSIS [J].
MARTYN, CN ;
ILLIS, LS ;
THOM, J .
LANCET, 1995, 345 (8949) :579-579
[19]   EFFECT OF CANNABINOIDS ON SPASTICITY AND ATAXIA IN MULTIPLE-SCLEROSIS [J].
MEINCK, HM ;
SCHONLE, PW ;
CONRAD, B .
JOURNAL OF NEUROLOGY, 1989, 236 (02) :120-122
[20]   Multiple sclerosis: Symptomatic therapies [J].
Metz, L .
SEMINARS IN NEUROLOGY, 1998, 18 (03) :389-395